Drugs effects on ventricular repolarization: A critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices

Journal of Pharmacological and Toxicological Methods

Volumn 52, Issue 1, 2005, Pages 12-21

  Bass, Alan S ^a   Tomaselli, Gordon ^c   Bullingham III, Roy ^d   Kinter, Lewis B ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ASTRAZENECA   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Daiichi Medical Research   (United States)

Author keywords

Potassium ion conductance; TdP; Ventricular repolarization

Indexed keywords

POTASSIUM CHANNEL HERG;

CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; COMPUTER MODEL; CONSENSUS DEVELOPMENT; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HEART ARRHYTHMIA; HEART CELL CULTURE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; LONG QT SYNDROME; NONHUMAN; QT INTERVAL; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT;

EID: 22444444118     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2005.04.010     Document Type: Article

References (51)

1. Kr potassium channels with HERG and is associated with cardiac arrhythmia Cell 97 1999 175 187
2. M.M. Adamantidis, P. Kerram, J.F. Caron, and B.A. Dupuis Droperidol exerts dual effects on repolarization and induces early afterdepolarizations and triggered activity in rabbit Purkinje fibers Journal of Pharmacology and Experimental Therapeutics 266 1993 884 893
3. M.E. Anderson, S.M. Al-Khatib, D.M. Roden, and R.M. Califf Cardiac repolarization: Current knowledge, critical gaps and new approaches to drug development and patient management American Heart Journal 144 2002 769 781
4. Anon. (2001). US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Safety pharmacology studies for human pharmaceuticals (ICH S7A).
5. Anon. (2002). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. FDA preliminary concept paper.
6. Anon. (2005a). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14, Step 4, May 12, 2005.
7. Anon. (2005b). The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. (S7B), Step 4, May 12, 2005.
8. C. Antzelevitch, S. Sicouri, S.H. Litovsky, A. Lukas, S.C. Krishnan, and J.M. Di Diego Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells Circulation Research 69 1991 1427 1449
9. R.S. Aronson Afterpotentials and triggered activity in hypertrophied myocardium from rats with renal hypertension Circulation Research 48 1981 720 727
10. B. Balati, A. Varro, and J.G. Papp Comparison of the cellular electrophysiological characteristics of canine left ventricular myocardium, M cells, and endocardium and Purkinje fibers Acta Physiologica Scandinavica 164 1998 181 190
11. J. Barhanin, F. Lesage, E. Guillemare, M. Fink, M. Lazdunski, and G. Romey K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current [see comments] Nature 384 1996 78 80
12. A.S. Bass, L.B. Kinter, and P.D. Williams Origins, practices and future of safety pharmacology Journal of Pharmacological and Toxicological Methods 49 2004 145 151
13. L. Carlsson, O. Almgren, and G. Duker QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions Journal of Cardiovascular Pharmacology 16 1990 276 285
14. C.E. Chiang, and D.M. Roden The long QT syndromes: Genetic basis and clinical implications Journal of the American College of Cardiology 36 2000 1 12
15. Committee for Proprietary Medicinal Products (EU). (1997). Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP 986/96, 1-6 (http://www.emea.eu.int/ pdfs/human/swp/098696en.pdf).
16. M.E. Curran, I. Splawski, K.W. Timothy, G.M. Vincent, E.D. Green, and M.T. Keating A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome Cell 180 1995 795 803
17. F. De Ponti, E. Poluzzi, and N. Montanaro Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus European Journal of Clinical Pharmacology 57 2001 185 209
18. C.D. Dota, N. Edvardsson, and G. Fager Individual correction of QT intervals for RR dependence: 80 years after Dr. Bazett NASPE 22nd Annual Scientific Sessions, Boston, May 2-5, Abstr. 781 2001
19. + conduction and selectivity [see comments] Science 280 1998 69 77
20. P. Duggal, M.R. Vesely, D. Wattanasirichaigoon, J. Villafane, V. Kaushik, and A.H. Beggs Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long-QT syndrome Circulation 97 1998 142 146
21. Y. Gan-Xin, W. Shimizu, and C. Antzelevitch Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations Circulation 98 1998 1921 1927
22. V. Gjini, J. Schreieck, M. Korth, S. Weyerbrock, A. Schomig, and C. Schmitt Frequency dependence in the action of the Class III antiarrhythmic drug dofetilide is modulated by altering L-type calcium current and digitalis glucoside Journal of Cardiovascular Pharmacology 31 1998 95 100
23. R.L. Hamlin, C.A. Cruze, S.W. Mittelstadt, A. Kijtawornrat, B.W. Keene, and B.M. Roche Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc Journal of Pharmacological and Toxicological Methods 49 2004 15 23
24. W. Haverkamp, G. Breithart, A.J. Camm, M.J. Janse, M.R. Rosen, and C. Antzelevitch The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications Cardiovascular Research 47 2000 219 233
25. Health Canada. (2001). Therapeutic Products Directorate Guidance Document (Canada). Assessment of the QT prolongation potential of non-antiarrhythmic drugs (http://www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/guidmain.html).
26. L.M. Hondeghem, L. Carlsson, and G. Duker Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic Circulation 103 2001 204 2013
27. L.B. Kinter, P.K.S. Siegl, and A.S. Bass New preclinical guidelines on drug effects on ventricular repolarization: Safety pharmacology comes of age! Journal of Pharmacological and Toxicological Methods 49 3 2004 153 158
28. L.B. Kinter, and J.P. Valentin Safety pharmacology and risk assessment Fundamental & Clinical Pharmacology 16 2002 175 182
29. E. Lepeschkin, and B. Surawicz The measurement of the QT interval of the electrocardiogram Circulation 6 1952 378 388
30. + current in guinea pig ventricular myocytes Cardiovascular Drugs and Therapy 16 2005 317 325
31. M. Malik Heart rate correction for the assessment of drug induced QT interval prolongation NASPE 22nd annual scientific sessions, Boston, May 2-5, Abstr. 348 2001
32. E. Marban, S.W. Robinson, and W.G. Wier Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle Journal of Clinical Investigation 78 1986 1185 1192
33. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M.C. Sanguinetti A structural basis for drug-induced long QT syndrome Proceedings of the National Academy of Sciences of the United States of America 97 2000 12329 12333
34. P.J. Mohler, A.O. Gramolini, and V. Bennett The Ankyrin-B C-terminal domain determines activity of Ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-triphosphate and ryanodine receptor distribution in Ankyrin (-/-) neonatal cardiomyocytes Journal of Biological Chemistry 277 2002 10599 10607
35. A.J. Moss The QT interval and torsade de pointes Drug Safety 21 1999 5 10
36. I. Neviana, W.J. Crumb, J.D. Pigott, L.H. Harrison Jr., and C.W. Clarkson Quinidine interactions with human atrial potassium channels Circulation Research 83 1998 1224 1231
37. W.S. Redfern, L. Carlsson, S. Davis, W.G. Lynch, I. MacKenzie, and S. Palethorpe Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation, and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development Cardiovascular Research 58 1 2003 32 45
38. J.J. Salata, N.K. Jurkiewicz, A.A. Wallace, R.F. Stupienski III, P.J. Guinosso Jr., and J.J. Lynch Jr. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine Circulation Research 76 1995 110 119
39. M.C. Sanguinetti, M.E. Curran, A. Zou, J. Shen, P.S. Spector, and D.L. Atkinson Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel [see comments] Nature 384 1996 80 83
40. K. Schroeder, B. Neagle, D. Trezise, and J. Worley Ionworks HT: A new high-throughput electrophysiology measurement platform Journal of Biomolecular Screening 8 1 2003 50 64
41. W. Shimizu, and C. Antzelevitch Cellular and ionic basis for T-wave alternans under long-QT conditions Circulation 99 1999 1499 1507
42. S. Spence, K. Soper, C.-M. Hoe, and J. Coleman The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance Physiological Sciences 45 1998 247 258
43. A.E. Taylor Ovascular effects of environmental chemicals Otolaryngology-Head and Neck Surgery 114 2 1996 209 211
44. R. Temple Are surrogate markers adequate to assess cardiovascular disease drugs? Journal of the American Medical Association 282 1999 790 795
45. S.H.L. Thomas Drugs, QT interval abnormalities and ventricular arrhythmias Adverse Drug Reactions and Toxicological Reviews 13 1994 77 102
46. G.F. Tomaselli, D.J. Beuckelmann, H.G. Calkins, R.D. Berger, P.D. Kessler, and J.H. Lawrence Sudden cardiac death in heart failure. The role of abnormal repolarization Circulation 90 1994 2534 2539
47. G.F. Tomaselli, and E. Marban Electrophysiological remodeling in hypertrophy and heart failure Cardiovascular Research 42 1999 270 283
48. S. Usdin, and K. Haan The QT mandate BioCentury 11 24 2003 A1 A5
49. Q. Wang, J. Shen, I. Splawski, D. Atkinson, Z. Li, and J.L. Robinson SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome Cell 80 1995 805 811
50. J. Weissenburger, J.M. Davy, F. Chezalviel, O. Ertzbischoff, J.M. Poirier, and F. Engel Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol Journal of Pharmacology and Experimental Therapeutics 259 1991 871 883
51. Kr: Model, systems and relevance to human arrhythmias Journal of Cardiovascular Pharmacology 38 2001 737 744